Antibody Information

General Information of This Antibody

Antibody ID	ANI0OGIEK
Antibody Name	Anti-BCMA antibody L15
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1-kappa
Antigen Name	Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)	Antigen Info
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Varible Domain	EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISGQSNYIYY ADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGNYFVEYFQYWGQGTLVTVSS Click to Show/Hide
Light Chain Constant Domain	EIVLTQSPGTLSLSPGERATLSCRASQYISSNNLAWYQQKPGQAPRLLIYGASNRATGIP DRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTKLEIK Click to Show/Hide

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

Anti-BCMA L15-SG3249 [Investigative]

ADC Info

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.16% (Day 21)	Moderate BCMA expression (BCMA++)
Method Description	Mice were treated with either a single intravenous dose of ADCs at 1 mg/kg, or dosed intravenously with J6M0-mc-MMAF ADC weekly at a dose of 1 mg/kg for 3 weeks. Control mice were left untreated.
In Vivo Model	JJN-3 CDX model
In Vitro Model	Plasma cell myeloma	JJN-3 cells		CVCL_2078
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.37% (Day 32)	Moderate BCMA expression (BCMA++)
Method Description	Mice were treated with either a single intravenous dose of ADCs at 1 mg/kg, or dosed intravenously with J6M0-mc-MMAF ADC weekly at a dose of 1 mg/kg for 4 weeks. Control mice were left untreated.
In Vivo Model	MM.1S CDX model
In Vitro Model	Plasma cell myeloma	MM1.S cells		CVCL_8792
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.35% (Day 21)	High BCMA expression (BCMA+++)
Method Description	Mice were treated with either a single intravenous dose of the ADCs at 0.3 mg/kg or dosed intravenously with J6M0-mc-MMAFweekly at a dose of 0.3 mg/kg for 2 weeks.
In Vivo Model	NCI-H929 CDX model
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600

References

Ref 1	Bcma monoclonal antibody-drug conjugate.